Natera, TransCode Therapeutics partner on Phase 2a colorectal cancer trial enrollment using Signatera MRD test
Natera entered a strategic collaboration with TransCode Therapeutics to support enrollment in a Phase 2a colorectal cancer trial. Signatera MRD testing will be used to identify eligible patients who remain MRD-positive after curative-intent therapy with no radiographic disease. Partnership targets faster site-level pat